A carregar...
Stepwise shortening of agalsidase beta infusion duration in Fabry disease: Clinical experience with infusion rate escalation protocol
BACKGROUND: Although enzyme replacement therapy with agalsidase beta resulted in a variety of clinical benefits, life‐long biweekly intravenous infusion may impact on patients’ quality of life. Moreover, regular infusions are time‐consuming: although a stepwise shortening of infusion duration is all...
Na minha lista:
| Publicado no: | Mol Genet Genomic Med |
|---|---|
| Main Authors: | , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
John Wiley and Sons Inc.
2021
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8172210/ https://ncbi.nlm.nih.gov/pubmed/33755336 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/mgg3.1659 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|